This company listing is no longer active
TBP Stock Overview
A biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Tetra Bio-Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.025 |
| 52 Week High | CA$0.075 |
| 52 Week Low | CA$0.015 |
| Beta | 2.26 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -58.33% |
| 3 Year Change | -88.64% |
| 5 Year Change | -96.48% |
| Change since IPO | 0% |
Recent News & Updates
Shareholder Returns
| TBP | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 1.5% |
| 1Y | -58.3% | -62.1% | 10.3% |
Return vs Industry: TBP underperformed the Canadian Pharmaceuticals industry which returned -55.8% over the past year.
Return vs Market: TBP underperformed the Canadian Market which returned -6.6% over the past year.
Price Volatility
| TBP volatility | |
|---|---|
| TBP Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 12.8% |
| Market Average Movement | 9.7% |
| 10% most volatile stocks in CA Market | 17.8% |
| 10% least volatile stocks in CA Market | 4.1% |
Stable Share Price: TBP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TBP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 33 | Guy Chamberland | www.tetrabiopharma.com |
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma.
Tetra Bio-Pharma Inc. Fundamentals Summary
| TBP fundamental statistics | |
|---|---|
| Market cap | CA$12.89m |
| Earnings (TTM) | -CA$39.02m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs TBP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TBP income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$39.02m |
| Earnings | -CA$39.02m |
Last Reported Earnings
Aug 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.076 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -28.1% |
How did TBP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/06/03 08:47 |
| End of Day Share Price | 2023/03/06 00:00 |
| Earnings | 2022/08/31 |
| Annual Earnings | 2021/11/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tetra Bio-Pharma Inc. is covered by 1 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rahul Sarugaser | Paradigm Capital, Inc. |